São Paulo, Brazil, 10 July 2022 — Recently, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) held a seminar at the International Congress of Endovascular Surgery (Congresso International de Cirurgia Endovascular, CICE 2022) in Brazil, engaging local and global experts.
The CICE, which was initiated in Brazil, has today become one of the leading international congresses in the field of vascular surgeries. Focusing on endovascular surgeries, the CICE addresses a spectrum of cutting-edge applications and highlights current unmet clinical needs and hot topics. CICE 2022 was held face-to-face for the first time in nearly three years since the COVID-19 outbreak.
During the CICE, Endovastec™ exhibited its homegrown innovative products for aortic intervention, including the Castor™ Branched Aortic Stent-Graft System ("Castor™), the Minos™ Abdominal Aortic Stent-Graft and Delivery System, and the Hercules™ Low Profile Tubular Stent-Graft System, which generated significant attention and interactions among participants.
In the discussion session, Prof. Chang Shu, Director of the Vascular Surgery Center of Fuwai Hospital, Chinese Academy of Medical Sciences, China, and Prof. Guilherme Vieira Meirelles of Novo Hospital, Brazil, addressed the application of the Castor™ Stent in the treatment of aortic dissection, citing the clinical experience of experts from Asia and South America.
Prof. Chang Shu shared information on the application of HENDO techniques for treating aortic arch lesions, including Hybrid arch repair, Endovascular repair, and Open arch repair. Compared with open surgery and hybrid arch repair, reconstructing the aortic arch branches through endovascular repair has the merits of minimal trauma, short operative time, and rapid postoperative recovery. The key to this approach lies in the adoption of a stent-graft to isolate the lesion while preserving or reconstructing the important branch arteries within the anchor zone using minimally invasive assisted techniques. Prof. Shu noted that: "The Castor™ features a theoretically optimal anatomical design because of its unique unibody structure that seamlessly integrates the main body and the branch. Its unique unibody structure not only conforms to a wide range of arch anatomy, but also reduces surgical trauma risk.”
Prof. Meirelles shared a case of the application of Castor™ in type B aortic dissection. The patient’s aortic dissection retrograded from the left subclavian artery (LSA) to the iliac artery, with preoperative CT revealing stenosis and ulceration of the true lumen. Based on an evaluation of surgical challenges, the team opted for LSA reconstruction by introducing and precisely releasing the Castor™ stent graft at the lesion site. The 6-month postoperative follow-up and imaging data demonstrated an effective reconstruction of the LSA with satisfactory patency and fully-covered ulceration.
As the world’s first market-approved branched aortic stent-graft, the innovative Castor™ Branched Aortic Stent-Graft System developed by Endovastec™ was presented at the CICE conference after its debut in Brazil in 2020, attracting attention and recognition by the vascular surgery community in South America for its underlying technology. In the future, Endovastec™ will continue to be committed to introducing more and better innovative products for aortic and peripheral vascular interventions for the benefit of more patients with blood circulation diseases worldwide.
Founded in Shanghai in 2012, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™", stock code: 688016.SH), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is a global medical device company focusing on R&D, manufacturing, and sales of aortic and peripheral vascular interventional devices. Its product portfolio includes thoracic and abdominal aortic stent grafts, intraoperative stents, drug-coated PTA balloon catheters, and PTA balloon catheters. At Endovastec™, we are breaking barriers and accelerating access to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping life, and to build a people-centric enterprise as a global leader of evolving and emerging medical technologies through continuous innovation.
More information is available at www.endovastec.com.